Neuberger Berman Group
PCRX icon

Neuberger Berman Group’s Pacira BioSciences PCRX Stock Holding History

Neuberger Berman Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
+10,405
New +$246K ﹤0.01% 2070
2025
Q3 		– Sell
-8,382
Closed -$200K – 2123
2025
Q2 		$200K Buy
+8,382
New +$211K ﹤0.01% 1892
2022
Q2 		– Sell
-18,489
Closed -$1.41M – 1907
2022
Q1 		$1.41M Buy
18,489
+9,680
+110% +$645K ﹤0.01% 1272
2021
Q4 		$525K Sell
8,809
-26,840
-75% -$1.48M ﹤0.01% 1535
2021
Q3 		$2M Sell
35,649
-15,510
-30% -$894K ﹤0.01% 1170
2021
Q2 		$3.1M Sell
51,159
-7,087
-12% -$449K ﹤0.01% 1078
2021
Q1 		$4.08M Buy
58,246
+37,484
+181% +$2.68M ﹤0.01% 998
2020
Q4 		$1.24M Buy
20,762
+3,613
+21% +$212K ﹤0.01% 1206
2020
Q3 		$1.03M Buy
+17,149
New +$996K ﹤0.01% 1211
2017
Q2 		– Sell
-32,500
Closed -$1.48M – 1630
2017
Q1 		$1.48M Buy
+32,500
New +$1.4M ﹤0.01% 1069
2016
Q2 		– Sell
-21,067
Closed -$1.12M – 1572
2016
Q1 		$1.12M Buy
21,067
+6,805
+48% +$398K ﹤0.01% 1084
2015
Q4 		$1.09M Sell
14,262
-259,201
-95% -$14.7M ﹤0.01% 1110
2015
Q3 		$11.2M Buy
273,463
+155,395
+132% +$9.52M 0.01% 759
2015
Q2 		$8.35M Sell
118,068
-109,453
-48% -$8.62M 0.01% 859
2015
Q1 		$20.2M Buy
227,521
+25,994
+13% +$2.64M 0.02% 691
2014
Q4 		$17.9M Sell
201,527
-71,727
-26% -$6.78M 0.02% 696
2014
Q3 		$26.5M Buy
273,254
+109,543
+67% +$10.7M 0.03% 593
2014
Q2 		$15M Buy
163,711
+70,921
+76% +$5.4M 0.01% 732
2014
Q1 		$6.49M Buy
92,790
+37,155
+67% +$2.53M 0.01% 890
2013
Q4 		$3.2M Buy
55,635
+12,665
+29% +$666K ﹤0.01% 968
2013
Q3 		$2.07M Sell
42,970
-36,280
-46% -$1.32M ﹤0.01% 1041
2013
Q2 		$2.3M Buy
+79,250
New +$2.29M ﹤0.01% 1014

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's PCRX Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 10,405 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #2070 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in PCRX as recently as Q2 2025.

Neuberger Berman Group first reported a position in PCRX in Q2 2013 and has held it in 22 quarters since. The position peaked at $26.5M in Q3 2014. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Neuberger Berman Group held 10,405 shares of Pacira BioSciences worth $264K as of Q2 2026.
  • Pacira BioSciences was a new Neuberger Berman Group position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2070 holding.
  • Neuberger Berman Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 22 quarters since.
  • Neuberger Berman Group's Pacira BioSciences position peaked at $26.5M in Q3 2014.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.